Pending

Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain-derived α-synuclein.
Urinary proteome profiling for stratifying patients with familial Parkinson’s disease.
Study of the Fecal Microbiome in Patients With Parkinson’s Disease
Mitophagy Impairment in Neurodegenerative Diseases: Pathogenesis and Therapeutic Interventions.
Targeting Mitochondrial Impairment in Parkinson’s Disease: Challenges and Opportunities.
Quantum dot conjugated saporin activates microglia and induces selective substantia nigra degeneration.
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study.
Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson’s disease.
Therapeutic Role of Protein Tyrosine Phosphatase 1B in Parkinson’s Disease via Antineuroinflammation and Neuroprotection In Vitro and In Vivo.
Therapies for Genetic Forms of Parkinson’s Disease: Systematic Literature Review.
Mitochondrial transplant to replenish damaged mitochondria: A novel therapeutic strategy for neurodegenerative diseases?
Blood biomarkers with Parkinson’s disease clusters and prognosis: The oxford discovery cohort.
Extracellular Vesicles in the Treatment of Parkinson’s Disease: A Review.
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.
18F-DOPA II – PET Imaging Optimization
Botulinum Toxin in Movement Disorders: An Update.
Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management.
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative diseases.
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model.
ERRγ ligand HPB2 upregulates BDNF-TrkB and enhances dopaminergic neuronal phenotype.
Novel approaches to counter protein aggregation pathology in Parkinson’s disease.
Target Molecules of STIM Proteins in the Central Nervous System.
Recent findings leading to the discovery of selective dopamine D4 receptor ligands for the treatment of widespread diseases.
Facilitation of GluN2C-containing NMDA receptors in the external globus pallidus increases firing of fast spiking neurons and improves motor function in a hemiparkinsonian mouse model.
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Posttranslational modifications as therapeutic targets for intestinal disorders.
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson’s disease.
Novel Associations of BST1 and LAMP3 with Rapid Eye Movement Sleep Behavior Disorder.
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson’s disease.
StimVision v2: Examples and Applications in Subthalamic Deep Brain Stimulation for Parkinson’s Disease.
Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease.
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease.
Fisetin Regulates Gut Microbiota and Exerts Neuroprotective Effect on Mouse Model of Parkinson’s Disease.
Huang Lian Jie Du Tang attenuates paraquat-induced mitophagy in human SH-SY5Y cells: A traditional decoction with a novel therapeutic potential in treating Parkinson’s disease.
Relative Bioavailability and Bioequivalence of Opicapone
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson’s Disease
Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study.
Cell Senescence in Neuropathology: a Focus on Neurodegeneration and Tumours.
The Stanford Parkinson’s Disease Plasma Study
Self-inflating floating nanofiber membranes for controlled drug delivery.
The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson’s Disease Patients
MPTP-induced mouse model of Parkinson’s disease: A promising direction of therapeutic strategies.
Glutathione peroxidase-1 and neuromodulation: novel potentials of an old enzyme.
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson’s Disease
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
Innovative Applications of MR-Guided Focused Ultrasound for Neurological Disorders.
Design of a virtual longitudinal observational study in Parkinson’s disease (AT-HOME PD).
Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease.
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
Subthalamic Nucleus Deep Brain Stimulation Modulates 2 Distinct Neurocircuits.
Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease.
Cancer and Parkinson’s Disease: Common Targets, Emerging Hopes.
Interventional pain management in patients with cancer-related pain.
Distinct subthalamic coupling in the ON state describes motor performance in Parkinson’s disease.
The role of the gut microbiota in the pathophysiology of mental and neurological disorders.
Neuromodulation Options and Patient Selection for Parkinson’s Disease.
Nanotheranostic agents for neurodegenerative diseases.
PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape.
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.
Smart neuromodulation in movement disorders.
Industrial perspectives on brain-computer interface technology.
Mdm2 enhances ligase activity of parkin and facilitates mitophagy.
Emerging novel approaches to drug research and diagnosis of Parkinson’s disease.
Extracellular vesicles – propagators of neuropathology and sources of potential biomarkers and therapeutics for neurodegenerative diseases.
Targeting Microglia for Therapy of Parkinson’s Disease by Using Biomimetic Ultrasmall Nanoparticles.
Aging-related modifications to G protein-coupled receptor signaling diversity.
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
Extracellular Vesicles and Damage-Associated Molecular Patterns: A Pandora’s Box in Health and Disease.
Genetic mechanisms of critical illness in Covid-19.
Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease.
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Cerebral sterile inflammation in neurodegenerative diseases.
A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival.
New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease.
Closed-loop neuromodulation for clustering neuronal populations.
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson’s Disease
PasoDoble, a Proposed Dance/Music for People With Parkinson’s Disease and Their Caregivers.
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms.
Liver Growth Factor “LGF” as a Therapeutic Agent for Alzheimer’s Disease.
Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations.
Entacapone promotes hippocampal neurogenesis in mice.
Auricular Muscle Zone Stimulation for Parkinson Disease
A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson’s Disease (PD)
Dual Frequency Stimulation in Parkinson’s Disease
Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness.
DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease.
Using machine learning-based analytics of daily activities to identify modifiable risk factors for falling in Parkinson’s disease.
Neuroprotective and Neurotoxic Effects of Endocannabinoid-like compounds, N-Arachidonoyl Dopamine and N-Docosahexaenoyl Dopamine in Differentiated Cultures of Induced Pluripotent Stem Cells Derived from Patients with Parkinson’s Disease.
A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model.
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Proteomic Profiling of Mitochondrial-Derived Vesicles in Brain Reveals Enrichment of Respiratory Complex Sub-assemblies and Small TIM Chaperones.
Immune-associated biomarkers for early diagnosis of Parkinson’s disease based on hematological lncRNA-mRNA co-expression.
Spectral guided sparse inverse covariance estimation of metabolic networks in Parkinson’s disease.
Characterization of EEG Data Revealing Relationships With Cognitive and Motor Symptoms in Parkinson’s Disease: A Systematic Review.
Sprouted oat as a potential gluten-free ingredient with enhanced nutritional and bioactive properties.

Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson’s disease treatment.
Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson’s Disease
Palliative care and Parkinson’s disease: outpatient needs and models of care over the disease trajectory.
Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson’s disease.
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ Episodes.
An Open-label Safety Study of Pimavanserin in Parkinson’s Disease Patients
A Study to Evaluate SAGE-217 in Participants With Parkinson’s Disease
Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinson’s Disease.
Antiferroptotic Activity of Phenothiazine Analogues: A Novel Therapeutic Strategy for Oxidative Stress Related Disease.
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson’s Disease
Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson’s Disease -Treatment
Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson’s Disease
Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.
Parkinson’s Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Development and evaluation of a novel music-based therapeutic device for upper extremity movement training: A pre-clinical, single-arm trial.
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned.
Vercise Implantable Stimulator for Treating Parkinson’s Disease
Dual-task Augmented Reality Treatment for Parkinson’s Disease
Coeliac disease in childhood: An overview.
Chemical compounds with a neuroprotective effect from the seeds of Celosia argentea L.
Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes.
E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.
The Role of Exosomal microRNAs and Oxidative Stress in Neurodegenerative Diseases.
Current updates in transdermal therapeutic systems and their role in neurological disorders.
In-silico prediction of the beta carboline alkaloids Harmine and Harmaline as potent drug candidates for the treatment of Parkinson’s disease.
The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein.
Therapeutics potentiating microglial p21-Nrf2 axis can rescue neurodegeneration caused by neuroinflammation.
Increased telomerase improves motor function and alpha-synuclein pathology in a transgenic mouse model of Parkinson’s disease associated with enhanced autophagy.
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
Neuroimaging Advances in Parkinson’s Disease and Atypical Parkinsonian Syndromes.
Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease.
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson’s Disease
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson’s disease model.
Curcumin Prevents Neuroinflammation by Inducing Microglia to Transform into the M2-phenotype via CaMKKβ-dependent Activation of the AMP-Activated Protein Kinase Signal Pathway.
Calbindin-D9k is a Novel Risk Gene for Neurodegenerative Disease.
Activation of Sirt1/PGC1α pathway attenuates neuroinflammation injury in Parkinson’s disease.
Molecular landscape of long noncoding RNAs in brain disorders.
Pivotal Role of Fyn Kinase in Parkinson’s Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
The use of peripheral blood mononuclear cells in celiac disease diagnosis and treatment.
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
High-Specificity Digital Architecture for Real-Time Recognition of Loss of Balance Inducing Fall.
Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment.
Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseases.
A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
Protective effect of thioredoxin reductase 1 in Parkinson’s disease.
Do the Bugs in Your Gut Eat Your Memories? Relationship between Gut Microbiota and Alzheimer’s Disease.
Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson’s disease models.
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
2-Hydroxy-4-Methylbenzoic Anhydride Inhibits Neuroinflammation in Cellular and Experimental Animal Models of Parkinson’s Disease.
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson’s Disease: A Pilot Study.
Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson’s Disease.
Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.
Autophagic receptor p62 protects against glycation-derived toxicity and enhances viability.
Automated Quantification of Mitochondrial Fragmentation in an In Vitro Parkinson’s Disease Model.
Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson’s Disease.
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson’s Disease
Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Stem Cell-Based Therapies for Parkinson Disease.
A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson’s disease.
Nanoparticles for drug delivery in Parkinson’s disease.
“Developing new treatments in partnership for Primary Mitochondrial Disease: what does industry need from academics, and what do academics need from industry?”
Perspective: Phase Amplitude Coupling-Based Phase-Dependent Neuromodulation in Parkinson’s Disease.
Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases.
Miro (Mitochondrial Rho GTPase), a key player of Mitochondrial axonal transport and Mitochondrial dynamics in Neurodegenerative diseases.
Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.
Dermatitis Herpetiformis: Novel Perspectives.
Identification of Molecular Network Associated with Neuroprotective Effects of Yashtimadhu (Glycyrrhiza glabra L.) by Quantitative Proteomics of Rotenone-Induced Parkinson’s Disease Model.
Genome-wide screening of mouse knockouts reveals novel genes required for normal integumentary and oculocutaneous structure and function.
Cholesterol metabolism and brain injury in neonatal encephalopathy.
Identification of Specific Circular RNA Expression Patterns and MicroRNA Interaction Networks in Mesial Temporal Lobe Epilepsy.
Upregulation of Cellular Palmitoylation Mitigates α-Synuclein Accumulation and Neurotoxicity.
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson’s Disease
Research progress on adenosine in central nervous system diseases.
FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
Demonstration of Kinematic-Based Closed-loop Deep Brain Stimulation for Mitigating Freezing of Gait in People with Parkinson’s Disease.
Quantification of Parkinson’s Disease Motor Symptoms: A Wireless Motion Sensing Approach.
Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics.
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson’s Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Telerehabilitation for Parkinson’s Disease
Nanomedicine against Alzheimer’s and Parkinson’s disease.
Current and emerging therapeutic targets for Parkinson’s disease.
Serotonergic System Impacts Levodopa Response in Early Parkinson’s and Future Risk of Dyskinesia.
A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214
Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson’s Therapeutics.
A case report of delayed diagnosis of danon disease: Caused by a newly recognized mutation in the lysosome-associated membrane protein-2 gene.
A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: Translational gaps or a failing industry innovation model?
Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease.
Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration.
Emerging role of S100B protein implication in Parkinson’s disease pathogenesis.
Perspective: Evolution of Control Variables and Policies for Closed-Loop Deep Brain Stimulation for Parkinson’s Disease Using Bidirectional Deep-Brain-Computer Interfaces.
Biomarker Assessments of Leukine During Treatment of Parkinson’s Disease
PK Study of WD-1603 in Healthy Subjects
eBrain: a Three Dimensional Simulation Tool to Study Drug Delivery in the Brain.

Synthesis and preliminary studies of 11C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2.
Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson’s Disease (PD) Symptoms and Biomarkers (MCT-PD)
Neuromodulation Effects of Deep Brain Stimulation on Beta Rhythm: A Longitudinal Local Field Potential Study.
Modulation of the Microbiome in Parkinson’s Disease: Diet, Drug, Stool Transplant, and Beyond.
Applications of Acupuncture Therapy in Modulating the Plasticity of Neurodegenerative Disease and Depression: Do MicroRNA and Neurotrophin BDNF Shed Light on the Underlying Mechanism?
Molecular evolutionary and structural analysis of human UCHL1 gene demonstrates the relevant role of intragenic epistasis in Parkinson’s disease and other neurological disorders.
The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders.
[The role of the gut microbiome in idiopathic Parkinson’s disease].
A novel wireless brain stimulation device for long-term use in freely moving mice.
Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients
Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson’s Disease.
Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease.
OLE Study for Patients With Parkinson’s Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies.
Exploring celiac disease candidate pathways by global gene expression profiling and gene network cluster analysis.
Parkinson’s Disease Isradipine Safety Study
Factors That Influence Habitual Activity in Mild Cognitive Impairment and Dementia.
Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation.
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Treatment of Chronic Constipation in Parkinson’s Disease
The application of iPSCs in Parkinson’s disease.
Rho kinase inhibitor fasudil reduces L-DOPA-induced dyskinesia in a rat model of Parkinson´s disease.
Quantitative Mapping of Substantia Nigra Iron in Parkinson’s Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Artificial intelligence in celiac disease.
Pyrroloquinoline Quinone Inhibits Rotenone-Induced Microglia Inflammation by Enhancing Autophagy.
Opioid Modulation of Neuronal Iron and Potential Contributions to NeuroHIV.
Home Based Tele-exercise for People With Chronic Neurological Impairments: COVID and Beyond
Gene therapy for neurodegenerative disorders: advances, insights and prospects.
An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobes.
The Role of Exosomes in Stemness and Neurodegenerative Diseases-Chemoresistant-Cancer Therapeutics and Phytochemicals.
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus.
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson’s Disease
Surgical Treatment of Parkinson Disease.
Discovery of a Series of Ester-substituted NLRP3 Inflammasome Inhibitors.
Extracellular Vesicles as Nanotherapeutics for Parkinson’s Disease.
Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism.
Parkin-linked Parkinson’s disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches.
The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke.
An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions
Cyclized NDGA modifies dynamic α-synuclein monomers preventing aggregation and toxicity.
VGLUT2 EXPRESSION IN DOPAMINE NEURONS CONTRIBUTES TO POST-LESIONAL STRIATAL REINNERVATION.
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Feasibility and Acceptability of a Physical Activity Behavior Change Intervention for Parkinson’s Disease
Treating Anxiety in Parkinson’s Disease With a Multi-Strain Probiotic
Microglial inflammation and phagocytosis in Alzheimer’s disease: Potential therapeutic targets.
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer’s Disease, Parkinson’s Disease, and Intracerebral Hemorrhage.
A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson’s disease.
An Increased Burden of Highly Active Retrotransposition Competent L1s Is Associated with Parkinson’s Disease Risk and Progression in the PPMI Cohort.
Calcium imaging in freely-moving mice during electrical stimulation of deep brain structures.
Neurodegenerative Disease-Related Proteins within the Epidermal Layer of the Human Skin.
Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)
Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer’s disease?
Noncoding RNAs and Midbrain DA Neurons: Novel Molecular Mechanisms and Therapeutic Targets in Health and Disease.
Spermidine inhibits neurodegeneration and delays aging via the PINK1-PDR1-dependent mitophagy pathway in C. elegans.
Subthalamic Deep Brain Stimulation (DBS) in Parkinson’s Disease
Resistant Maltodextrin for Gut Microbiome in Parkinson’s Disease: Safety and Tolerability Study
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson’s Disease With Motor Fluctuations
A Study of KW-6356 in Patients With Parkinson’s Disease on Treatment With Levodopa-containing Preparations
The SUMO conjugase Ubc9 protects Dopaminergic cells from cytotoxicity and enhances the stability of α-synuclein in Parkinson’s disease models.
A Novel Tri-culture Model for Neuroinflammation.
Probiomimetics-Novel Lactobacillus-Mimicking Microparticles Show Anti-Inflammatory and Barrier-Protecting Effects in Gastrointestinal Models.
A Novel Small Molecule Supports the Survival of Cultured Dopamine Neurons and May Restore the Dopaminergic Innervation of the Brain in the MPTP Mouse Model of Parkinson’s Disease.
Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.
Varenicline for Gait and Balance Impairment in Parkinson Disease
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models.
Safety and Efficacy of Pimavanserin in Adults With Parkinson’s Disease and Depression
Machine learning discriminates a movement disorder in a zebrafish model of Parkinson’s disease.
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.
Tetramethylpyrazine ameliorates isoflurane-induced cognitive dysfunction by inhibiting neuroinflammation via miR-150 in rats.
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.
Phase 2 Clinical Study of KW-6500 in Parkinson’s Disease Patients With Motor Response Complication on Levodopa Therapy
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
State-dependent Pathophysiological Oscillations in Parkinson’s Disease and Treatment With Deep Brain Stimulation (DBS)
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson’s Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
Determination of oxyphylla A enantiomers in the fruits of Alpinia oxyphylla by a chiral HPLC-MRM-MS method and comparison of their in vivo biological activities.
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson’s Disease
The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions and the general population.
Unique Novel role of Adropin in the gastric Ulcer in a rotenone-induced Rat model of Parkinson’s disease.
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer’s and Parkinson’s Patients
tDCS-Enhanced Consolidation of Writing Skills and Its Associations With Cortical Excitability in Parkinson Disease: A Pilot Study.
Maternal bacteria to correct abnormal gut microbiota in babies born by C-section.
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review.
Ghrelin mitigates MPP+-induced cytotoxicity: involvement of ERK1/2-mediated Nrf2/HO-1 and endoplasmic reticulum stress PERK signaling pathway.
Dopamine receptors in emesis: molecular mechanisms and potential therapeutic function.
Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia.
Manganese Induced neurodegenerative diseases and possible therapeutic approaches.
Transferrin1 modulates rotenone-induced Parkinson’s disease through affecting iron homeostasis in Drosophila melanogaster.
Effectiveness of Botox on Reducing Rest Tremor in Parkinson’s Disease
Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases.
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
Gutting the brain of inflammation: A key role of gut microbiome in human umbilical cord blood plasma therapy in Parkinson’s disease model.
An experience-based review of HIFU in functional interventional neuroradiology: transcranial MRgFUS thalamotomy for treatment of tremor.
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by “OFF” Episodes
Therapeutic Potential for Intranasal Levodopa in Parkinson’s Disease -Off Reversal
Modeling the metabolic interplay between a parasitic worm and its bacterial endosymbiont allows the identification of novel drug targets.

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson’s Disease Complicated by Motor Fluctuations “OFF” Episodes
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD
Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions.
Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases.
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson’s disease in the precision medicine era.
Biofluid Markers for Prodromal Parkinson’s Disease: Evidence From a Catecholaminergic Perspective.
A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review.
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson’s Disease
Fecal Microbiota Transplantation As a Potential Treatment for Parkinson’s Disease
Tau aggregation and seeding analyses of two novel MAPT variants found in patients with motor neuron disease and progressive parkinsonism.
Attenuation of epigenetic regulator SMARCA4 and ERK-ETS signaling suppresses aging-related dopaminergic degeneration.
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Image guidance in deep brain stimulation surgery to treat Parkinson’s disease: a comprehensive review.
Status and future directions of clinical trials in Parkinson’s disease.
Community-based genetic study of Parkinson´s disease in Estonia.
Updated but not outdated “Gliadin”: A plant protein in advanced pharmaceutical nanotechnologies.
Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson’s disease.
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients With Parkinson’s Disease.
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.
CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
Microglia and astrocyte dysfunction in parkinson’s disease.
Amburana cearensis: Pharmacological and Neuroprotective Effects of Its Compounds.
Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson’s Disease.
A Study to Examine APL-130277 in Patients With Parkinson’s Disease
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson’s Disease
Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson’s disease.
The Role of Neurovascular System in Neurodegenerative Diseases.
Dopaminergic Loss and Pain in Parkinson’s Disease
Adrenergic Blockers for Cardiac Changes in Early Parkinson’s Disease
Outcomes Mandate National Integration With Cannabis as Medicine
Tocotrienols in Parkinson’s Disease (PD)
Study of Urate Elevation in Parkinson’s Disease, Phase 3
Reciprocal Upshot of Nitric Oxide, Endoplasmic Reticulum Stress, and Ubiquitin Proteasome System in Parkinson’s Disease Pathology.
Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration.
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson’s disease: A case series.
The class II histone deacetylases as therapeutic targets for Parkinson’s disease.
Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
Natural Products as Modulators of Sirtuins.
An update on the therapeutic potential of calpain inhibitors: a patent review.
Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease
Phase 2b Follow-on Safety “Roll-over” Study
Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases.
Demystifying autoimmune small bowel enteropathy.
Chronic diarrhoea in adults: what not to miss.
A Study to Evaluate ENT-01 for the Treatment of Parkinson’s Disease Dementia
Gluten Degrading Enzymes for Treatment of Celiac Disease.
Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1α signaling pathway and mitochondrial uncoupling protein -2(UCP-2).
Neuroepigenetics of arousal: Gamma oscillations in the pedunculopontine nucleus.
Gene therapy, a novel therapeutic tool for neurological disorders: Current progress, challenges and future prospective.
Neurorestorative Effects of a Novel Fas-Associated Factor 1 Inhibitor in the MPTP Model: An [18F]FE-PE2I Positron Emission Tomography Analysis Study.
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases.
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson’s Disease Mild Cognitive Impairment (PD-MCI)
Integrated Binary QSAR-Driven Virtual Screening and in vitro Studies for Finding Novel hMAO-B-Selective Inhibitors.
G-protein coupled receptor 88 knockdown in the associative striatum reduces psychiatric symptoms in a translational male rat model of Parkinson disease.
Rationally engineered prolyl endopeptidases from Sphingomonas capsulata with improved hydrolytic activity towards pathogenic peptides of celiac diseases.
Tolerance to NeuroEPO in Parkinson Disease
Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention.
Does altering proteasomal activity and trafficking reduce the arborization mediated specific vulnerability of SNpc dopaminergic neurons of Parkinson’s disease?
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method.
“The whole perimeter is difficult”: Parkinson’s disease and the conscious experience of walking in everyday environments.
Epigenetic Basis of Lead-Induced Neurological Disorders.
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson’s Disease
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson’s Disease Dementia
[Movement Disorders: What Are You Doing? What Can We Do?]
FDOPA PET and Nutritional Support in Parkinson’s Disease
New insights into cortico-basal-cerebellar connectome: clinical and physiological considerations.
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson’s disease mice model.
GSK-3β inhibition by curcumin mitigates amyloidogenesis via TFEB activation and anti-oxidative Activity in human neuroblastoma cells.
Transcranial magnetic stimulation and gait disturbances in Parkinson’s disease: A systematic review.
Deciphering short stature in children.
Role of Long Noncoding RNAs in Parkinson’s Disease: Putative Biomarkers and Therapeutic Targets.
A Large-Scale Full GBA1 Gene Screening in Parkinson’s Disease in the Netherlands.
Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson’s Disease.
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Isolation of LMX1a Ventral Midbrain Progenitors Improves the Safety and Predictability of Human Pluripotent Stem Cell-Derived Neural Transplants in Parkinsonian Disease.
Complex Effects of Putative DRP-1 Inhibitors on Stress Responses in Mouse Heart and Rat Cardiomyoblasts.
Improvement of lower urinary tract function by a selective serotonin 5-HT1A receptor agonist, NLX-112, after chronic spinal cord injury.
A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China
A Clinical Study Trial of Phenlarmide in China
Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson’s Disease
A novel mutation of indoleamine 2,3-dioxygenase 1 causes a rapid proteasomal degradation and compromises protein function.
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
Human gene therapy approaches for the treatment of Parkinson’s disease: An overview of current and completed clinical trials.
Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders.
Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease.
Probiotics-prebiotic Fiber Therapy in Parkinson’s Disease Patients With Constipation
Design and in vitro analysis of SIRT2 inhibitor targeting Parkinson’s disease.
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson’s disease.
Maackiain Ameliorates 6-Hydroxydopamine and SNCA Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson’s Disease in Caenorhabditis elegans and the SH-SY5Y Cell Line.
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson’s Disease
Parkinson’s disease: etiopathogenesis and treatment.
A novel pyrazolo [3,4-d] pyrimidine, KKC080106, activates the Nrf2 pathway and protects nigral dopaminergic neurons.

Integrated robotics platform with haptic control differentiates subjects with Parkinson’s disease from controls and quantifies the motor effects of levodopa.
Genomewide association study of Parkinson’s disease clinical biomarkers in 12 longitudinal patients’ cohorts.
Ambroxol as a Treatment for Parkinson’s Disease Dementia
Ambient Air Pollution Increases the Risk of Cerebrovascular and Neuropsychiatric Disorders through Induction of Inflammation and Oxidative Stress.
Advancing gene therapies, methods, and technologies for Parkinson’s Disease and other neurological disorders.
Pigment Epithelium-Derived Factor Affects Angiogenesis in Celiac Disease.
Novel Strategies for Gene Therapy-Recent Advances in the Use of Exosomes for Disease Treatment.
Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish.
Proteomic profiling of striatal tissue of a rat model of Parkinson’s disease after implantation of collagen-encapsulated human umbilical cord mesenchymal stem cells.
A Clinical Study of Mesdopetam in Patients With Parkinson’s Disease Experiencing Levodopa Induced Dyskinesia
Does outpatient palliative care improve patient-centered outcomes in Parkinson’s disease: Rationale, design, and implementation of a pragmatic comparative effectiveness trial.
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson’s Disease
Nasal Resistance (NR) Technique: A Novel Approach to Improve Glottal Adduction.
“LRRK2: Autophagy and Lysosomal Activity”.
High Frequency Oscillations in Neurologic Disease
EIn vivo modeling of prodromal stage of Parkinson’s disease.
Clinical utility of SUDOSCAN in predicting autonomic neuropathy in patients with Parkinson’s disease.
Chronic Effects of DBS in Parkinson’s Disease and Dystonia
Stereotactic Transplantation of hAESCs for Parkinson’s Disease
Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome.
Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson’s Disease.
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease by regulating inducible nitric-oxide synthase.
Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson’s disease.
Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia.
Detecting Common Pathways and Key Molecules of Neurodegenerative Diseases from the Topology of Molecular Networks.
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson’s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
Multifaceted targeting of neurodegeneration with bioactive molecules of saffron (Crocus sativus): An insilco evidence-based hypothesis.
A thin-film multichannel electrode for muscle recording and stimulation in neuroprosthetics applications.
Cholinergic Mechanisms of Gait Dysfunction in Parkinson’s Disease Exp. 3 – Proj#3 (UdallP3)
The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease.
Restoration of CTSD (cathepsin D) and lysosomal function in stroke is neuroprotective.
Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?
Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson’s disease treatment?
Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis.
Mitophagy in Parkinson’s Disease: from pathogenesis to treatment target.
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Safety and Biomarker Study of EPI-589 in Parkinson’s Disease
Combining data integration and molecular dynamics for target identification in α-Synuclein-aggregating neurodegenerative diseases: Structural insights on Synaptojanin-1 (Synj1).
Gold nanoclusters for Parkinson’s disease treatment.
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways.
Wearable Ultrasound Improves Motor Function in an MPTP Mouse Model of Parkinson’s Disease.
Immediate effects of rhythmic auditory stimulation on gait kinematics in Parkinson’s disease ON/OFF medication.
Cholinergic Mechanisms of Gait Dysfunction in Parkinson’s Disease – Proj#3
Invasive and Noninvasive Brain Stimulation in Parkinson’s Disease: Clinical Effects and Future Perspectives.
Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study.
Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease.
Terazosin Effect on Cardiac Changes in Early Parkinson’s Disease
Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid.
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson’s disease.
A simulated environment for early development stages of reinforcement learning algorithms for closed-loop deep brain stimulation.
Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
Improving Walking Automaticity in Parkinson’s Disease: Levodopa or Donepezil
Safety and Efficacy of Liraglutide in Parkinson’s Disease
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson’s Disease
PLA2 G4E, a candidate gene for resilience in Alzheimer´s disease and a new target for dementia treatment.
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson’s Disease
Study in Parkinson’s Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy.
“Sick-but-not-dead”: Multiple paths to catecholamine deficiency in Lewy Body diseases.
Four main therapeutic keys for Parkinson’s disease: A mini review.
A novel alpha-lipoic acid-3-n-butylphthalide conjugate enhances protective effects against oxidative stress and 6-OHDA induced neuronal damage.
PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases.
Neuroimaging Technological Advancements for Targeting in Functional Neurosurgery.
Chronic 2-Fold Elevation of Endogenous GDNF Levels Is Safe and Enhances Motor and Dopaminergic Function in Aged Mice.
A Clinical Study in Advanced Parkinson’s Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion
Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes.
Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression.
A Two-Stage Tremor Detection Algorithm for Wearable Inertial Sensors During Normal Daily Activities.
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson’s Disease on Stable Dopaminergic Treatment
The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration.
Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria.
A method to specifically activate the Klotho promoter by using zinc finger proteins constructed from modular building blocks and from naturally engineered Egr1 transcription factor backbone.
Pain-Induced Beta Activity in the Subthalamic Nucleus of Parkinson’s Disease.
Clonazepam improves the symptoms of two siblings with novel variants in the SYNJ1 gene.
Walking to Music and Metronome at Various Tempi in Persons With Multiple Sclerosis: A Basis for Rehabilitation.
Identification of biomarkers associated with Parkinson’s disease by gene expression profiling studies and bioinformatics analysis.
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
The Messenger Apps of the cell: Extracellular Vesicles as Regulatory Messengers of Microglial Function in the CNS.
Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients.
Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments.
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders.
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study.
Mitochondrial Dysfunction and Parkinson’s Disease-Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy.
Pain in Parkinson’s disease: new concepts in pathogenesis and treatment.
Discovery of Novel Compounds Targeting DJ-1 as Neuroprotectants for Parkinson’s Disease by Virtual Screening and in Silico Method.
Early Expression of Neuronal Dopaminergic Markers in a Parkinson’s Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs).
Caring Interactions in Secondary Prevention Programs: A Qualitative Inquiry of Individuals With Parkinson’s Disease.
Role of flavonoids in neurodegenerative diseases: Limitations and future perspectives.
Structural and Functional Evidence for Citicoline Binding and Modulation of 20S Proteasome Activity: Novel Insights into its Pro-Proteostatic Effect.
GDNF Promotes Survival and Therapeutic Efficacy of Human Adipose-Derived Mesenchymal Stem Cells in a Mouse Model of Parkinson’s Disease.
Ambroxol in Disease Modification in Parkinson Disease
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease
The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson’s Disease

Lipid-based nanoformulations in the treatment of neurological disorders.
A preliminary study of Parkinson’s gene therapy via sono-magnetic sensing gene vector for conquering extra/intracellular barriers in mice.
Effects of Transcranial Direct Current Stimulation on Postural Control
Phase I, KM-819 in Healthy Subjects for Parkinson’s Disease
A Through QT/QTc Study of KW-6356
Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements.
Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders.
Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson’s Disease:
The Relationship Between Neuropsychological Testing and MRI, PET and COBRE – Project 1: AIM 2 (GE-180)
PK Study in Patients With Parkinson’s Disease With IZD174
Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update.
ORALLY ADMINISTERED NANOTHERAPEUTICS FOR PARKINSON DISEASE: AN OLD DELIVERY SYSTEM YET MORE ACCEPTABLE.
Effect of TAK-071 on Falls in Patients With Parkinson Disease
The gut microbiome in Parkinson’s disease: A culprit or a bystander?
Mechanisms of alpha-synuclein toxicity: An update and outlook.
Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset.
Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson’s disease via suppressions of CRMP2 phosphorylation and microglial activation.
Bio Electro Stimulation Therapy for Parkinson’s Disease
Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson’s Disease
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson’s Disease.
The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease.
Dopaminergic restauratIon by intraVEntriculaire Administration
Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review.
Safety and Tolerability Study of K0706 in Subjects With Parkinson’s Disease
Analysis of Functional and Cognitive Impairment in Institutionalized Individuals with Movement Disorders.
5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease.
A Clinical Study of KDT-3594 in Patients With Early Parkinson’s Disease.
Neurorehabilitation Improves the Motor Features in Prodromal SCA2: A Randomized, Controlled Trial.
Therapeutic Potential of Diosgenin and Its Major Derivatives against Neurological Diseases: Recent Advances.
Recent advances in the therapeutic development for Huntington disease.
Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain.
Exosomes from Human Periapical Cyst-MSCs: Theranostic Application in Parkinson’s Disease.
Safety and Efficacy of CERE-120 in Subjects With Parkinson’s Disease
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson’s Disease
Speech-in-Noise Treatments for Hypophonia in Parkinson’s Disease
Study Investigating Effects of Foliglurax in Patients With Parkinson’s Disease (PD) and Healthy Subjects
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases.
Genetic networks in Parkinson’s and Alzheimer’s disease.
Peroxiredoxin 5 deficiency exacerbates iron overload-induced neuronal death via ER-mediated mitochondrial fission in mouse hippocampus.
PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial.
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.
Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase.
In vitro investigations on dopamine loaded Solid Lipid Nanoparticles.
inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Novel Management of Airway Protection in Parkinson’s Disease: A Clinical Trial
Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease.
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
Systematic review of gene expression studies in people with Lewy Body Dementia.
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease
BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations
Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism.
Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.
Exenatide Treatment in Parkinson’s Disease
Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy
Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells.
A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s
A Study to Investigate a New Treatment in Patients With Parkinson’s Disease
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson’s Disease
ANAVEX2-73 Study in Parkinson’s Disease Dementia
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease.
Assessment of Deep Brain Stimulation Implantation Surgery: A Practical Scale.
Inflammation in neurological disorders: the thin boundary between brain and periphery.
Initiation and propagation of α-synuclein aggregation in the nervous system.
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
A 2-Part Trial of CVL-751 in Subjects With Parkinson’s Disease
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson’s disease model mice.
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson’s Disease
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson’s Disease
Double triggers, nasal induction of a Parkinson’s disease mouse model.
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease.
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson’s Disease
VY-AADC02 for Parkinson’s Disease With Motor Fluctuations
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson’s Disease
Lu AF28996 in Patients With Parkinson’s Disease (PD)
Ultrasound-responsive neurotrophic factor-loaded microbubble- liposome complex: Preclinical investigation for Parkinson’s disease treatment.
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson’s Disease?
Aerobic Exercise in Parkinson’s Disease
Gut, oral and nasal microbiota and Parkinson’s disease.
OHI–Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease.
Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson’s Disease Agents.
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease
Deep brain stimulation of the ventroanterior and ventrolateral thalamus improves motor function in a rat model of Parkinson’s disease.
Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication.
Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease
Effect of Exercise in Parkinsonism
Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson’s Disease
Managing autonomic dysfunction in Parkinson’s disease: a review of emerging drugs.
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson’s Disease.
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson’s Disease
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease.
Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease.
Metabolic Cofactor Supplementation in Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) Patients
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson’s Disease

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias
Walking to your right music: a randomized controlled trial on the novel use of treadmill plus music in Parkinson’s disease.
Neuroprotective and Neurotherapeutic Effects of Tetrahedral Framework Nucleic Acids on Parkinson’s Disease in Vitro.
Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism.
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease’s Patients
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
Development of a novel oral delivery vehicle for probiotics.
Repetitive Motor Control Deficits Most Consistent Predictors of Conversion to Freezing of Gait in Parkinson’s Disease: A Prospective Cohort Study.
Safety and Efficacy of DA-9805 for Parkinson’s Disease
Unraveling correlative roles of Dopamine transporter (DAT) and Parkin in Parkinson’s disease (PD) – A road to discovery?
Chronic infiltration of T lymphocytes into the brain in a non-human primate model of Parkinson’s disease.
Synergy between plasminogen activator inhibitor-1, α-synuclein, and neuroinflammation in Parkinson’s disease.
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson’s Disease (PD)
Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target.
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease.
Neuroprotective mechanisms of S-allyl-L-cysteine in neurological disease.
Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?
RGS proteins as critical regulators of motor function and their implications in Parkinson’s disease.
Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer’s, Parkinson’s and Prion’s.
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
Evaluation of Neuroinflammation in Parkinson’s Disease Using 18F-NOS PET/CT
Intranasal Insulin in Parkinson’s Disease
Social Decision Making in Parkinson’s Disease
Emerging Role of Sirtuin 2 in Parkinson’s Disease.
Could Heat Therapy Be an Effective Treatment for Alzheimer’s and Parkinson’s Diseases? A Narrative Review.
Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury.
Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Sequoia Study)
Clinical Effect Durability of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Redwood Study)
rTMS to Improve Cognition in Parkinson’s
Terazosin for Parkinson’s Disease
Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond.
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease.
Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson’s (PD).
[18F]F-DOPA Imaging in Patients With Autonomic Failure
iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates.
Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays.
T-495, a novel low cooperative M1 receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk.
Clinical Laboratory Evaluation of Chronic Autonomic Failure
Immunotherapy for Parkinson’s disease.
Vesicular Dysfunction and the Pathogenesis of Parkinson’s Disease: Clues From Genetic Studies.
Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders.
Emerging therapies in Parkinson disease – repurposed drugs and new approaches.
Structure-based development of caged dopamine D2/D3 receptor antagonists.
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease.
Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
Use of Low-dose Zolpidem in Parkinson’s Disease
Initial Investigation of [18F]P17-059 in Parkinson’s Disease Patients and Healthy Volunteers
A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson’s Disease
iHandU: A Novel Quantitative Wrist Rigidity Evaluation Device for Deep Brain Stimulation Surgery.
Detailed in vitro pharmacological characterization of the clinically viable NOP receptor antagonist BTRX-246040.
Scutellarin Inhibits the Uninduced and Metal-Induced Aggregation of ɑ-Synuclein and Disaggregates Preformed Fibrils: Implications for Parkinson’s disease.
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Effects of Exenatide on Motor Function and the Brain
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson’s Disease
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Efficacy of Isradipine in Early Parkinson Disease
Infusion of Apomorphine: Long-term Safety Study
Measuring Parkinson’s Disease Progression
AV-101 (L-4-chlorokynurenine) in Parkinson’s Disease Subjects With Levodopa-Induced Dyskinesia
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
Pedunculopontine and Subthalamic Nucleus Stimulation Effect on Saccades in Parkinson Disease.
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease
Study to Evaluate DNL201 in Subjects With Parkinson’s Disease
Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease. Extension to HP-CD-CL-2002 Clinical Study
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson’s Disease
A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects
A Study in Parkinson’s Disease in paTients With mOderate to seveRe dyskInesiA
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)
Study to Evaluate DNL151 in Subjects With Parkinson’s Disease
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations (BouNDless).
VPS35-Based Approach: A Potential Innovative Treatment in Parkinson’s Disease.
Epigenetic Regulation of Excitatory Amino Acid Transporter 2 in Neurological Disorders.
Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases.
Novel Therapeutics for the treatment of Alzheimer’s and Parkinson’s disorders.
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Flexible-Dose Trial in Early Parkinson’s Disease (PD)
SC79, a novel Akt activator, protects dopaminergic neuronal cells from MPP+ and rotenone.
Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.
High and Low Dose Carbidopa Treatment of Parkinson’s Disease
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson’s Disease Psychosis
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson’s Disease and Excessive Sleepiness
A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson’s Disease Patients
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
Pyrethroid exposure and neurotoxicity: a mechanistic approach.
Deep brain stimulation of the pedunculopontine nucleus modulates subthalamic pathological oscillations.
Dopamine restores cognitive motivation in Parkinson’s disease.
Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited hemophilia B: a case report.
Cardiac Changes in Early Parkinson’s Disease: A Follow up Study
Systematic review of genetic association studies in people with Lewy body dementia.
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity.
Buspirone in Parkinson’s Disease
Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening.
Cerebellar functional abnormalities in early stage drug-naïve and medicated Parkinson’s disease.
Characterization of AN317, a novel selective agonist of α6β2-containing nicotinic acetylcholine receptors.
Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors.
Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein.

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson’s Disease (PD)
Extracellular Nanomatrix-Induced Self-Organization of Neural Stem Cells into Miniature Substantia Nigra-Like Structures with Therapeutic Effects on Parkinsonian Rats.
Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia.
Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity.
Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective.
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
Variable- versus constant-frequency deep-brain stimulation in patients with advanced Parkinson’s disease: study protocol for a randomized controlled trial.
AAV2-GDNF for Advanced Parkinson s Disease
GDNF Gene Therapy for Parkinson’s Disease
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson’s Disease (DYSCOVER)
Efficacy and Tolerability of IRL790 in Parkinson’s Disease Dyskinesia
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease
Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson’s Disease
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations
Stem cell therapy for neurological disorders: A focus on aging.
Phase-Dependent Suppression of Beta Oscillations in Parkinson’s Disease Patients.
The Horizon of Gene Therapy in Modern Medicine: Advances and Challenges.
Global ubiquitome analysis of substantia nigra in doubly-mutant human alpha-synuclein transgenic mice.
Deep brain stimulation of the substantia nigra for freezing of gait in Parkinson’s disease: is it about stimulation frequency?
2-Benzylidene-1-Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions.
Emerging Neuroprotective effect of Metformin in Parkinson’s disease: A Molecular crosstalk.
Simultaneous Stimulation of the Globus Pallidus Interna and the Nucleus Basalis of Meynert in the Parkinson-Dementia Syndrome.
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson’s Disease
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure
Fixed-Dose Trial in Early Parkinson’s Disease (PD)
A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival.
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson’s disease.
Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1).
Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson’s Disease in a Chinese Population.
An overview of the neuroendocrine system in Parkinson’s disease: what is the impact on diagnosis and treatment?
Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson’s Disease In Vitro and In Vivo.
BENZOTHIAZOLE-BASED LRRK2 INHIBITORS AS WNT ENHANCERS AND PROMOTERS OF OLIGODENDROCYTIC FATE.
Human Periapical Cyst-Derived Stem Cells Can Be A Smart “Lab-on-A-Cell” to Investigate Neurodegenerative Diseases and the Related Alteration of the Exosomes’ Content.
Zinc transporters in Alzheimer’s disease.
Mitochondrial calcium signaling as a therapeutic target for Alzheimer’s disease.
G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review.
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease.
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease.
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease.
A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson’s Disease Patients
A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson’s Disease (PD) or Dementia With Lewy Bodies (DLB)
Phase 2a Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson’s Disease (PD)
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects [Completed]
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson’s Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson’s Disease (PD)
Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson’s Disease
Trial of Ondansetron as a Parkinson’s HAllucinations Treatment
ANAVEX2-73 Study in Parkinson’s Disease Dementia
A simplified ultrasonography-guided approach for neurotoxin injection into the obliquus capitis inferior muscle in spasmodic torticollis.
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
Pilot Trial of Transnasal Nicotine in Parkinson Disease
High Frequency Oscillations in Neurologic Disease
Resistant Maltodextrin for Gut Microbiome in Parkinson’s Disease: Safety and Tolerability Study
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson’s Disease
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease
GST-4-Dependent Suppression of Neurodegeneration in C. elegans Models of Parkinson’s and Machado-Joseph Disease by Rapeseed Pomace Extract Supplementation.
GDNF-expressing Macrophages Restore Motor Functions at a Severe Late-stage, and Produce Long-Term Neuroprotective Effects at an Early-stage of Parkinson’s Disease in Transgenic Parkin Q311X(A) Mice.
Correlation between angiotensin 1-7-mediated Mas receptor expression with motor improvement, activated STAT3/SOCS3 cascade, and suppressed HMGB-1/RAGE/NF-κB signaling in 6-hydroxydopamine hemiparkinsonian rats.
Intravenous N-acetylcysteine for the Treatment of Gaucher’s Disease and Parkinson’s Disease
Parkinson’s Disease Therapy Using Cell Technology
The feasibility and acceptability of using a novel wrist worn cueing device to self-manage drooling problems in people with Parkinson’s disease: A pilot study.
Identification of PP2A and S6 Kinase as Modifiers of Leucine-Rich Repeat Kinase-Induced Neurotoxicity.
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease.
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson’s Disease
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson’s Disease
Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson’s Disease
Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease.
CuII (atsm) inhibits ferroptosis: implications for treatment of neurodegenerative disease.
Rifampicin attenuates rotenone-treated microglia inflammation via improving lysosomal function.
Pluronic gel-based burrowing assay for rapid assessment of neuromuscular health in C. elegans.
Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson’s Disease Models.
Are genetic and idiopathic forms of Parkinson’s disease the same disease?
Symptoms and medications change patterns for Parkinson’s disease patients stratification.
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.
Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases.
A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases.
The Future of Surgical Treatments for Parkinson’s Disease.
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Gene Therapy for Parkinson’s Disease, An Update.
Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task.
Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework.
Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson’s Disease
Motor Adaptation in Parkinson’s Disease During Prolonged Walking in Response to Corrective Acoustic Messages.
Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4).
Review-Novel synthetic curcuminoids: Not merely an anticancer agent.
Novel targets for parkinsonism-depression comorbidity.
SYT12 plays a critical role in oral cancer and may be a novel therapeutic target.

Generation and characterisation of a parkin-Pacrg knockout mouse line and a Pacrg knockout mouse line.
Sestrin2 as serum protein marker and potential therapeutic target for Parkinson’s Disease.
RQ-00000010 for Gastroparesis and Constipation in Parkinson’s Disease
Imaging Inflammation in Patients With Parkinson’s Disease Dementia or Dementia With Lewy Bodies
Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression.
rTMS on Motor Function of Parkinson’s Disease Patients With Different Phenotypes
Apomorphine Pump in Early Stage of Parkinson’s Disease (EARLY-PUMP)
Proceedings of the Sixth Deep Brain Stimulation Think Tank Modulation of Brain Networks and Application of Advanced Neuroimaging, Neurophysiology, and Optogenetics.
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
Tolerance to NeuroEPO in Parkinson Disease
Safety Study of Erythropoietin (EPO) in Parkinson’s Disease
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Selegiline: a molecule with innovative potential.
Non-human primate models of PD to test novel therapies.
Optimized programming algorithm for cylindrical and directional deep brain stimulation electrodes.
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson’s Disease.
Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.
Quantitative Mapping of Substantia Nigra Iron in Parkinson’s Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Dopamine acts via D2-like receptors to modulate auditory responses in the inferior colliculus.
A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway.
Nabilone for Non-motor Symptoms in Parkinson’s Disease
Nabilone for Non-motor Symptoms in Parkinson’s Disease
Aβ, Tau, and α-Synuclein aggregation and integrated role of PARK2 in the regulation and clearance of toxic peptides.
Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis.
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson’s Disease
White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy.
Rescue of Fmr1KO phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056.
An update on PTEN modulators – A patent review.
Terazosin for Parkinson’s Disease
B-SIDER: Computational Algorithm for the Design of Complementary β-sheet Sequences.
Outcomes Mandate National Integration With Cannabis as Medicine
DBS of the MLR for Gait and Balance Disorders in PD Patients
Genomewide association study of Parkinson’s disease clinical biomarkers in 12 longitudinal patients’ cohorts.
Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease.
Freezing of gait in Parkinson’s disease reflects a sudden derangement of locomotor network dynamics.
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment.
Glucose dysregulation in Parkinson’s disease: Too much glucose or not enough insulin?
Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.
Effect of Exercise in Parkinsonism
Innate immune responses to paraquat exposure in a Drosophila model of Parkinson’s disease.
Treatment with istradefylline for postural abnormalities in Parkinson’s disease.
Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease
Handwriting Interventions for People With Parkinson’s
Effectiveness of Botox on Reducing Rest Tremor in Parkinson’s Disease
Buffering of cytosolic calcium plays a neuroprotective role by preserving the autophagy-lysosome pathway during MPP+-induced neuronal death.
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson’s Disease
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
Twenty years on: Myoclonus-dystonia and ε-sarcoglycan – neurodevelopment, channel, and signaling dysfunction.
Aging Neurovascular Unit and Potential Role of DNA Damage and Repair in Combating Vascular and Neurodegenerative Disorders.
A new therapeutic strategy with istradefylline for postural deformities in Parkinson’s disease.
Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances, and Limitations.
Biopharmaceutical Monotargeting versus ‘Universal Targeting’ of Late-Onset Alzheimer’s Disease Using Mixtures of Pleiotropic Natural Compounds.
Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease.
Staccato Apomorphine Single and Multi Dose PK
Clinical implications of extracellular vesicles in neurodegenerative diseases.
Kinematic-guided BoNT-A Treatment for ET and PD Tremor
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson’s Disease
Evaluation of Neuroinflammation in Parkinson’s Disease Using 18F-NOS PET/CT
Mathematical Modeling for Description of Oscillation Suppression Induced by Deep Brain Stimulation.
Aerobic Exercise in Parkinson’s Disease
[Focused ultrasound ablation as tremor treatment].
Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders.
Spine MRI in DBS Patients
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells.
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
α-Arbutin Protects Against Parkinson’s Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo.
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson’s Patients
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson’s Disease
Designing Functionally Selective Non-Catechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Modafinil for Freezing of Gait (FOG) in Parkinson’s Disease (PD)
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson’s Disease
Study of the Fecal Microbiome in Patients With Parkinson’s Disease
A Cleaning Crew: The Pursuit of Autophagy in Parkinson’s Disease.
Efficacy and Tolerability of IRL790 in Parkinson’s Disease Dyskinesia
ANAVEX2-73 Study in Parkinson’s Disease Dementia
Metabolic Cofactor Supplementation in Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) Patients
Microbiota Intervention to Change the Response of Parkinson’s Disease
Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson’s (PD).
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson’s Disease
A Study of LY03003 in Patients With Early-stage Parkinson’s Disease
Mitophagy and Neuroprotection.
Genome-wide screening of mouse knockouts reveals novel genes required for normal integumentary and oculocutaneous structure and function.
Recent advances and challenges in the recovery and purification of cellular exosomes.
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
rTMS to Improve Cognition in Parkinson’s
Synthesis and preliminary evaluation of [11C]GNE-1023 as a novel potent PET probe for imaging leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease.
PF 06412562 in Subjects With Advanced Stage Parkinson’s Disease
Segmentation of the Globus Pallidus Internus Using Probabilistic Diffusion Tractography for Deep Brain Stimulation Targeting in Parkinson Disease.
Deltamethrin Intranasal administration induces memory, emotional and tyrosine hydroxylase immunoreactivity alterations in rats.
Current and future clinical utilities of Parkinson’s Disease and dementia biomarkers: can they help us conquer the disease?
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson’s Disease Patients With OFF Episodes
Long Term Safety and Efficacy Study of ProSavin in Parkinson’s Disease
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism.
[Modeling Familial Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells].
Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.

Tandem Mass Spectrometric Analysis of Novel Caffeine Scaffold-Based Bifunctional Compounds for Parkinson’s disease.
Biomarker Assessments of Leukine During Treatment of Parkinson’s Disease
SC79, a novel Akt activator, protects dopaminergic neuronal cells from MPP+ and rotenone.
Improving Walking Automaticity in Parkinson’s Disease: Levodopa or Donepezil
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson’s disease.
Mitophagy in Parkinson’s Disease: From Pathogenesis to Treatment.
The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective.
Evaluation of the Efficacy and Safety of Bumetanide in Parkinson’s Disease
Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation.
Monocyte Mobilisation, Microbiota & Mental Illness.
Vestibular heading perception in Parkinson’s disease.
Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative.
Novel Tools towards Magnetic Guidance of Neurite Growth: (I) Guidance of Magnetic Nanoparticles into Neurite Extensions of Induced Human Neurons and In Vitro Functionalization with RAS Regulating Proteins.
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease.
Methods to Investigate the Role of β-Arrestin Signaling in Parkinson’s Disease.
Genome Editing in Neurosciences
NEAT1 is overexpressed in Parkinson’s disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress.
Safety and Biomarker Study of EPI-589 in Parkinson’s Disease
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson’s Disease Psychosis
Cost-effectiveness of the HiBalance training program for elderly with Parkinson’s disease: analysis of data from a randomized controlled trial.
In Situ Peroxidase Labeling and Mass Spectrometry of Alpha-Synuclein in Rat Cortical Neurons.
Using Drosophila as a platform for drug discovery from natural products in Parkinson’s disease.
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease.
Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.
(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer’s disease challenged mice.
The Link between Gaucher Disease and Parkinson’s Disease Sheds Light on Old and Novel Disorders of Sphingolipid Metabolism.
Antagonistic Activity of Naphthoquinone-Based Hybrids toward Amyloids Associated with Alzheimer’s Disease and Type-2 Diabetes.
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
One decade ago, one decade ahead in progressive supranuclear palsy.
Apomorphine Nasal Powder in the Treatment of Parkinson’s Disease “Off” Periods.
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson’s Disease
Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents.
Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin Arm
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson’s Disease Model.
Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies.
Parkinson’s Disease Biomarkers based on Alpha-synuclein.
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Pragmatic Cyclical Lower Extremity Exercise Trial for Parkinson’s Disease
Effects of Transcranial Direct Current Stimulation on Postural Control
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson’s Disease Psychosis
Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure
Clinical Effect Durability of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure
Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson’s Disease:
Therapeutic Potential for Intranasal Levodopa in Parkinson’s Disease -Off Reversal
Acute kinematic and neurophysiological effects of treadmill and overground walking in Parkinson’s disease.
Safety and Efficacy of Pimavanserin in Adults With Parkinson’s Disease and Depression
Highly Challenging Balance Program to Reduce Fall Rate in PD
Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis.
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
Neuroimaging Technological Advancements for Targeting in Functional Neurosurgery.
Ammonium induced dysfunction of 5-HT2B receptor in astrocytes.
Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
Glial GLP1R: A novel neuroprotector?
Cueing for people with Parkinson’s disease with freezing of gait: A narrative review of the state-of-the-art and novel perspectives.
Imaging Transplantation in Movement Disorders.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
The Nucleus Basalis of Meynert and Its Role in Deep Brain Stimulation for Cognitive Disorders: A Historical Perspective.
LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Transcriptomics in Tissue Glucocorticoid Sensitivity.